 |
인쇄하기
취소
|
Once-monthly treatment for diabetes shows promise
A new diabetic medicine developed by a Korean drug maker has been under the first phase of clinical trials in the Netherlands and Korea.
The drug (codename: HM11260C), developed by Hanmi Pharmaceutical, a novel GLP-1 agonist for the treatment of type 2 diabetes.
Hanmi has initiated a Phase 1 clinical trial of HM11260C, which is based on LAPSCOVERY technology. LAPSCOVERY platform maximizes...
The drug (codename: HM11260C), developed by Hanmi Pharmaceutical, a novel GLP-1 agonist for the treatment of type 2 diabetes.
Hanmi has initiated a Phase 1 clinical trial of HM11260C, which is based on LAPSCOVERY technology. LAPSCOVERY platform maximizes...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.